

NEONATAL Medication Monograph

NEVIRAPINE

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires Neonatologist or Microbiologist review within 24 hours of initiation

A HIGH RISK Medication

Presentation	Oral Solution: 50mg/5mL = 10mg/mL			
Description	Non-nucleoside reverse transcriptase inhibitor Synergistic antiviral activity occurs when administered with zidovudine and lamivudine			
Indications	For the treatment of HIV infection in combination with other antiviral agents. Antiretroviral treatment regimens are determined on an individual			
Contraindications	basis Moderate to severe hepatic impairment			
Precautions	Hypersensitivity reactions			
Dosage	Dose regimens may vary dependent on an individual basis and maternal history			
	Given in combination with zidovudine and lamivudine			
	If mother has never taken nevirapine or was taking nevirapine for less than 3 days prior to birth			
	2 mg/ kg/ dose orally, daily for 1 week ,			
	Then 4 mg/ kg/ dose orally, daily for 1 week, then stop			
	If mother was taking nevirapine for the last 3 days or more prior to birth 4 mg/ kg/ dose, daily for 2 weeks, then stop			
Adverse	Common: rash, fever, diarrhoea			
Reactions	Serious: hepatotoxicity, neutropenia			

Preparation	Oral: Use undiluted		
Administration	May be given at any time with regards to feeds		
Monitoring	Liver function tests for long term use Neutrophil and haemoglobin count when infant is on combination therapy		
Storage	Store at room temperature, below 25°C		
Notes	Given in combination with zidovudine and lamivudine		
Related clinical guidelines	CAHS HIV Prevention in Infants Born to HIV Positive Women WNHS HIV Positive: management of the woman and her neonate		
Related policies	WNHS Policy: Antimicrobial Stewardship		
References	Truven Health Analytics. Nevirapine. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2020 Mar 13]. Available from: https://neofax.micromedexsolutions.com/ Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for		
	clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2019 Australian Society of Infectious Diseases 2014. Management of Perinatal Infections 2014. [cited 2020 Mar 13]. Available from: https://www.asid.net.au/documents/item/368		

Keywords:	HIV, nevirapine, HIV positive mother				
Publishing:					
Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	October 2008	Version:	3.0		
Last reviewed:	March 2020	Next review date:	March 2023		
Endorsed by:	Neonatal Directorate Management Group	Date:	March 2020		
Standards Applicable:	NSQHS Standards: 1 Governance, 3 Infection Control, 4 Medication Safety				

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2019